Phoenix-based Caris Diagnostics has developed a genetic test that can help identify colon cancer patients most likely to benefit from treatment with chemotherapy in tandem with tailored cancer drugs, such as ImClone Systems' Erbitux and Amgen's Vectibix. The combination of a test and a targeted medication shows the potential of personalized therapies in drug delivery, Caris CEO Dr. Robert Penny said.

Related Summaries